Non-opioid Pain Treatment Market Size, Share, and Trends 2024 to 2034

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis 

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on Non-opioid Pain Treatment Market 

5.1. COVID-19 Landscape: Non-opioid Pain Treatment Industry Impact

5.2. COVID 19 - Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global Non-opioid Pain Treatment Market, By Drug Class

8.1. Non-opioid Pain Treatment Market, by Drug Class, 2024-2034

8.1.1. NSAIDs

8.1.1.1. Market Revenue and Forecast (2021-2034)

8.1.2. Acetaminophen

8.1.2.1. Market Revenue and Forecast (2021-2034)

8.1.3. Local Anesthetics

8.1.3.1. Market Revenue and Forecast (2021-2034)

8.1.4. Others

8.1.4.1. Market Revenue and Forecast (2021-2034)

Chapter 9. Global Non-opioid Pain Treatment Market, By Pain Type

9.1. Non-opioid Pain Treatment Market, by Pain Type, 2024-2034

9.1.1. Chronic Pain

9.1.1.1. Market Revenue and Forecast (2021-2034)

9.1.2. Post-operative Pain

9.1.2.1. Market Revenue and Forecast (2021-2034)

9.1.3. Cancer Pain

9.1.3.1. Market Revenue and Forecast (2021-2034)

9.1.4. Others

9.1.4.1. Market Revenue and Forecast (2021-2034)

Chapter 10. Global Non-opioid Pain Treatment Market, By Route of Administration 

10.1. Non-opioid Pain Treatment Market, by Route of Administration, 2024-2034

10.1.1. Oral

10.1.1.1. Market Revenue and Forecast (2021-2034)

10.1.2. Topical

10.1.2.1. Market Revenue and Forecast (2021-2034)

10.1.3. Injectable

10.1.3.1. Market Revenue and Forecast (2021-2034)

10.1.4. Others

10.1.4.1. Market Revenue and Forecast (2021-2034)

Chapter 11. Global Non-opioid Pain Treatment Market, By Distribution Channel 

11.1. Non-opioid Pain Treatment Market, by Distribution Channel, 2024-2034

11.1.1. Hospital Pharmacy

11.1.1.1. Market Revenue and Forecast (2021-2034)

11.1.2. Retail Pharmacy

11.1.2.1. Market Revenue and Forecast (2021-2034)

11.1.3. Others

11.1.3.1. Market Revenue and Forecast (2021-2034)

Chapter 12. Global Non-opioid Pain Treatment Market, Regional Estimates and Trend Forecast

12.1. North America

12.1.1. Market Revenue and Forecast, by Drug Class (2021-2034)

12.1.2. Market Revenue and Forecast, by Pain Type (2021-2034)

12.1.3. Market Revenue and Forecast, by Route of Administration (2021-2034)

12.1.4. Market Revenue and Forecast, by Distribution Channel (2021-2034)

12.1.5. U.S.

12.1.5.1. Market Revenue and Forecast, by Drug Class (2021-2034)

12.1.5.2. Market Revenue and Forecast, by Pain Type (2021-2034)

12.1.5.3. Market Revenue and Forecast, by Route of Administration (2021-2034)

12.1.5.4. Market Revenue and Forecast, by Distribution Channel (2021-2034)

12.1.6. Rest of North America

12.1.6.1. Market Revenue and Forecast, by Drug Class (2021-2034)

12.1.6.2. Market Revenue and Forecast, by Pain Type (2021-2034)

12.1.6.3. Market Revenue and Forecast, by Route of Administration (2021-2034)

12.1.6.4. Market Revenue and Forecast, by Distribution Channel (2021-2034)

12.2. Europe

12.2.1. Market Revenue and Forecast, by Drug Class (2021-2034)

12.2.2. Market Revenue and Forecast, by Pain Type (2021-2034)

12.2.3. Market Revenue and Forecast, by Route of Administration (2021-2034)

12.2.4. Market Revenue and Forecast, by Distribution Channel (2021-2034)

12.2.5. UK

12.2.5.1. Market Revenue and Forecast, by Drug Class (2021-2034)

12.2.5.2. Market Revenue and Forecast, by Pain Type (2021-2034)

12.2.5.3. Market Revenue and Forecast, by Route of Administration (2021-2034)

12.2.5.4. Market Revenue and Forecast, by Distribution Channel (2021-2034)

12.2.6. Germany

12.2.6.1. Market Revenue and Forecast, by Drug Class (2021-2034)

12.2.6.2. Market Revenue and Forecast, by Pain Type (2021-2034)

12.2.6.3. Market Revenue and Forecast, by Route of Administration (2021-2034)

12.2.6.4. Market Revenue and Forecast, by Distribution Channel (2021-2034)

12.2.7. France

12.2.7.1. Market Revenue and Forecast, by Drug Class (2021-2034)

12.2.7.2. Market Revenue and Forecast, by Pain Type (2021-2034)

12.2.7.3. Market Revenue and Forecast, by Route of Administration (2021-2034)

12.2.7.4. Market Revenue and Forecast, by Distribution Channel (2021-2034)

12.2.8. Rest of Europe

12.2.8.1. Market Revenue and Forecast, by Drug Class (2021-2034)

12.2.8.2. Market Revenue and Forecast, by Pain Type (2021-2034)

12.2.8.3. Market Revenue and Forecast, by Route of Administration (2021-2034)

12.2.8.4. Market Revenue and Forecast, by Distribution Channel (2021-2034)

12.3. APAC

12.3.1. Market Revenue and Forecast, by Drug Class (2021-2034)

12.3.2. Market Revenue and Forecast, by Pain Type (2021-2034)

12.3.3. Market Revenue and Forecast, by Route of Administration (2021-2034)

12.3.4. Market Revenue and Forecast, by Distribution Channel (2021-2034)

12.3.5. India

12.3.5.1. Market Revenue and Forecast, by Drug Class (2021-2034)

12.3.5.2. Market Revenue and Forecast, by Pain Type (2021-2034)

12.3.5.3. Market Revenue and Forecast, by Route of Administration (2021-2034)

12.3.5.4. Market Revenue and Forecast, by Distribution Channel (2021-2034)

12.3.6. China

12.3.6.1. Market Revenue and Forecast, by Drug Class (2021-2034)

12.3.6.2. Market Revenue and Forecast, by Pain Type (2021-2034)

12.3.6.3. Market Revenue and Forecast, by Route of Administration (2021-2034)

12.3.6.4. Market Revenue and Forecast, by Distribution Channel (2021-2034)

12.3.7. Japan

12.3.7.1. Market Revenue and Forecast, by Drug Class (2021-2034)

12.3.7.2. Market Revenue and Forecast, by Pain Type (2021-2034)

12.3.7.3. Market Revenue and Forecast, by Route of Administration (2021-2034)

12.3.7.4. Market Revenue and Forecast, by Distribution Channel (2021-2034)

12.3.8. Rest of APAC

12.3.8.1. Market Revenue and Forecast, by Drug Class (2021-2034)

12.3.8.2. Market Revenue and Forecast, by Pain Type (2021-2034)

12.3.8.3. Market Revenue and Forecast, by Route of Administration (2021-2034)

12.3.8.4. Market Revenue and Forecast, by Distribution Channel (2021-2034)

12.4. MEA

12.4.1. Market Revenue and Forecast, by Drug Class (2021-2034)

12.4.2. Market Revenue and Forecast, by Pain Type (2021-2034)

12.4.3. Market Revenue and Forecast, by Route of Administration (2021-2034)

12.4.4. Market Revenue and Forecast, by Distribution Channel (2021-2034)

12.4.5. GCC

12.4.5.1. Market Revenue and Forecast, by Drug Class (2021-2034)

12.4.5.2. Market Revenue and Forecast, by Pain Type (2021-2034)

12.4.5.3. Market Revenue and Forecast, by Route of Administration (2021-2034)

12.4.5.4. Market Revenue and Forecast, by Distribution Channel (2021-2034)

12.4.6. North Africa

12.4.6.1. Market Revenue and Forecast, by Drug Class (2021-2034)

12.4.6.2. Market Revenue and Forecast, by Pain Type (2021-2034)

12.4.6.3. Market Revenue and Forecast, by Route of Administration (2021-2034)

12.4.6.4. Market Revenue and Forecast, by Distribution Channel (2021-2034)

12.4.7. South Africa

12.4.7.1. Market Revenue and Forecast, by Drug Class (2021-2034)

12.4.7.2. Market Revenue and Forecast, by Pain Type (2021-2034)

12.4.7.3. Market Revenue and Forecast, by Route of Administration (2021-2034)

12.4.7.4. Market Revenue and Forecast, by Distribution Channel (2021-2034)

12.4.8. Rest of MEA

12.4.8.1. Market Revenue and Forecast, by Drug Class (2021-2034)

12.4.8.2. Market Revenue and Forecast, by Pain Type (2021-2034)

12.4.8.3. Market Revenue and Forecast, by Route of Administration (2021-2034)

12.4.8.4. Market Revenue and Forecast, by Distribution Channel (2021-2034)

12.5. Latin America

12.5.1. Market Revenue and Forecast, by Drug Class (2021-2034)

12.5.2. Market Revenue and Forecast, by Pain Type (2021-2034)

12.5.3. Market Revenue and Forecast, by Route of Administration (2021-2034)

12.5.4. Market Revenue and Forecast, by Distribution Channel (2021-2034)

12.5.5. Brazil

12.5.5.1. Market Revenue and Forecast, by Drug Class (2021-2034)

12.5.5.2. Market Revenue and Forecast, by Pain Type (2021-2034)

12.5.5.3. Market Revenue and Forecast, by Route of Administration (2021-2034)

12.5.5.4. Market Revenue and Forecast, by Distribution Channel (2021-2034)

12.5.6. Rest of LATAM

12.5.6.1. Market Revenue and Forecast, by Drug Class (2021-2034)

12.5.6.2. Market Revenue and Forecast, by Pain Type (2021-2034)

12.5.6.3. Market Revenue and Forecast, by Route of Administration (2021-2034)

12.5.6.4. Market Revenue and Forecast, by Distribution Channel (2021-2034)

Chapter 13. Company Profiles

13.1. Novartis AG

13.1.1. Company Overview

13.1.2. Product Offerings

13.1.3. Financial Performance

13.1.4. Recent Initiatives

13.2. Teva Pharmaceutical Industries Limited

13.2.1. Company Overview

13.2.2. Product Offerings

13.2.3. Financial Performance

13.2.4. Recent Initiatives

13.3. Dr. Reddy’s Laboratories Ltd

13.3.1. Company Overview

13.3.2. Product Offerings

13.3.3. Financial Performance

13.3.4. Recent Initiatives

13.4. Sun Pharmaceutical Industries Ltd

13.4.1. Company Overview

13.4.2. Product Offerings

13.4.3. Financial Performance

13.4.4. Recent Initiatives

13.5. GSK plc.

13.5.1. Company Overview

13.5.2. Product Offerings

13.5.3. Financial Performance

13.5.4. Recent Initiatives

13.6. Pfizer Inc.

13.6.1. Company Overview

13.6.2. Product Offerings

13.6.3. Financial Performance

13.6.4. Recent Initiatives

13.7. Perrigo Company plc,

13.7.1. Company Overview

13.7.2. Product Offerings

13.7.3. Financial Performance

13.7.4. Recent Initiatives

13.8. LNK International, Inc.

13.8.1. Company Overview

13.8.2. Product Offerings

13.8.3. Financial Performance

13.8.4. Recent Initiatives

13.9. Cipla Inc.

13.9.1. Company Overview

13.9.2. Product Offerings

13.9.3. Financial Performance

13.9.4. Recent Initiatives

13.10. Johnson & Johnson Services, Inc.

13.10.1. Company Overview

13.10.2. Product Offerings

13.10.3. Financial Performance

13.10.4. Recent Initiatives

Chapter 14. Research Methodology

14.1. Primary Research

14.2. Secondary Research

14.3. Assumptions

Chapter 15. Appendix

15.1. About Us

15.2. Glossary of Terms